

Beaver, Nate

From: Stewart, Kendra <Kendra.Stewart@fda.hhs.gov>
Sent: Thursday, October 12, 2017 10:54 AM
To: Beaver, Nate
Subject: RE: Orange Book Listing Date

Dear Nathan Beaver,

Per Orange Book records, the '507 patent was listed on the Orange Book website on 5/19/2016 and the '240 patent was listed on 6/9/2016.

Regards,

CAPT Kendra S. Stewart, R.Ph., Pharm.D.
US Public Health Service
Supervisor, Orange Book Staff
Center for Drug Evaluation and Research
Office of Generic Drugs
U.S. Food and Drug Administration
Tel: 240-402-8797

ORANGE BOOK QUESTIONS: OrangeBook@fda.hhs.gov
WEBSITE: www.fda.gov/orangebook



From: NBeaver@foley.com [<mailto:NBeaver@foley.com>]
Sent: Wednesday, October 11, 2017 4:26 PM
To: Stewart, Kendra
Subject: Orange Book Listing Date

Dr. Stewart.

This follows up on a voicemail I left you earlier today. We represent United Therapeutics (UT) and are trying to confirm the date of publication in the Orange Book (i.e., the date the electronic OB was updated and patent information was publicly available) for two US Patents that were submitted by UT :

US Patent Nos. 9,339,507 and 9,358,240

These were submitted for listing by UT on 6/8/2016 for Tyvaso with respect to the '240 patent and on 5/17/2016 with respect to the '507 patent .

I am hoping that Orange Book Staff can confirm this information and respond by email with the actual date of listing in the OB.

Thank you.

Best regards,

Nate

Nathan A. Beaver, Partner
Foley & Lardner LLP – 3000 K St. NW, Suite 600
Washington, DC 20007
(p) 202-295-4039 – (f) 202-672-5399
nbeaver@foley.com

The preceding email message may be confidential or protected by the attorney-client privilege. It is not intended for transmission to, or receipt by, any unauthorized persons. If you have received this message in error, please (i) do not read it, (ii) reply to the sender that you received the message in error, and (iii) erase or destroy the message. Legal advice contained in the preceding message is solely for the benefit of the Foley & Lardner LLP client(s) represented by the Firm in the particular matter that is the subject of this message, and may not be relied upon by any other party.